| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2be1effe2aad8610d58162b6e1f93fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_426d35d703a26fe2e84dc65048f8748e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc384f4eb1a760c04a8af74a01eecff4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 |
| filingDate |
2015-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2959c6c36773abaea8562cdb7975eebc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ad891312a3512e16490228042c9045c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a295c42e6add00d9d5f56ad6557813e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c267f0729f5c9b297d7cb32c9dd6e48 |
| publicationDate |
2017-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3129032-A1 |
| titleOfInvention |
Galactoside inhibitors for the treatment of alpha-synucleinopthies |
| abstract |
The present invention relates to a pharmaceutical composition for use in a method for treatment or prevention of a-synucleinopathies wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain. The invention also concerns a method for treatment or prevention of a-synucleinopathies in a mammalian subject, the method comprising administering a therapeutically effective amount of at least one composition to the subject, wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain. |
| priorityDate |
2014-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |